Portfolio Expansion, Quarterly Dividends, Fresh Partnerships, and Strong Earnings Growth - Research Report on Agilent, Life Technologies, Mettler-Toledo, BD, and West

NEW YORK, August 1, 2013 /PRNewswire/ --

Today, Investors' Reports announced new research reports highlighting Agilent Technologies, Inc. (NYSE: A), Life Technologies Corporation (NASDAQ: LIFE), Mettler-Toledo International Inc. (NYSE: MTD), Becton, Dickinson and Company (NYSE: BDX), and West Pharmaceutical Services, Inc. (NYSE: WST). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Agilent Technologies, Inc. Research Report

On July 29, 2013, Agilent Technologies, Inc. (Agilent) announced that it will demonstrate some of its key product at EMC 2013, the IEEE International Symposium on Electromagnetic Compatibility, to be held from August 5 to August 9, 2013, at the Denver Convention Center in Denver, Colorado. Agilent informed that as part of the Global EMC and SI University series, Heidi Barnes, a Technical Expert at Agilent EEsof EDA, will present "Just How Good is Your SI Simulator?" The Full Research Report on Agilent Technologies, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-07-30/A]

--

Life Technologies Corporation Research Report

On July 25, 2013, Life Technologies Corporation (Life Technologies) announced the expansion of its global food safety portfolio with the worldwide distribution of the RT-qPCR assays for the detection of Norovirus GI and Norovirus GII, Hepatitis A, and the Mengovirus Extraction Control Kit by CEERAM (the European Centre for Expertise and Research on Microbial Agents).  Before the global distribution, the Company stated that the solutions were available only in Europe, Middle East, and Africa. The Company's Vice President and General Manager of Animal Health & Food Safety, Nir Nimrodi, said, "This global distribution deal with CEERAM broadens Life Technologies' already extensive portfolio of pathogen food safety solutions with these virus detection kits, providing food regulatory bodies and food manufacturers with access these high quality products." The Full Research Report on Life Technologies Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-07-30/LIFE]

--

Mettler-Toledo International Inc. Research Report

On July 25, 2013, Mettler-Toledo International Inc. (Mettler-Toledo) reported Q2 2013 financial results. Net earnings per diluted share for Q2 2013 were $2.24, higher as compared with $1.93 in Q2 2012. Adjusted EPS of $2.35 reflected an increase of 9.3% YoY. Further, the Company generated sales of $578.7 million in Q2 2013, representing a growth of 1.5% YoY. "Market conditions remain challenging, particularly in China. However, with continued strong execution in our various margin improvement and cost control initiatives, we generated good growth in EPS," said Olivier Filliol, President and CEO of Mettler-Toledo. The Full Research Report on Mettler-Toledo International Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-07-30/MTD]

--

Becton, Dickinson and Company Research Report

On July 23, 2013, Becton, Dickinson and Company (BD) announced that its Board of Directors has declared a quarterly dividend of c.$0.50 per share. The dividend is payable on September 30, 2013, to shareholders of record as of September 9, 2013. The Company reported that the indicated annual dividend rate is $1.98 per share. The Full Research Report on Becton, Dickinson and Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-07-30/BDX]

--

West Pharmaceutical Services, Inc. Research Report

On July 2, 2013, West Pharmaceutical Services, Inc. (West) announced the expansion of the NovaGuard portfolio of needle safety products. The Company informed that the NovaGuard SA system is now part of the NovaGuard system technology platform of syringe safety systems. According to the Company, prospective customers began evaluating NovaGuard SA in 2012, and West is expanding capacity to meet expected increases in market demand. Commenting on the expansion, Graham Reynolds, Vice President, Marketing and Innovation at West, said, "With our NovaGuard family of dependable, easy-to-use safety systems, we are able to meet growing market demand for safe drug delivery solutions worldwide and work together with our customers to create a healthier world." The Full Research Report on West Pharmaceutical Services, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-07-30/WST]

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

InvestorsReports.com

SOURCE Investors' Reports